GTBP GT Biopharma Inc
Price (delayed)
$2.36
Market cap
$5.27M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$6.94
Enterprise value
$1.23M
GT Biopharma, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of immuno-oncology therapeutic products based our proprietary TriKE™ NK cell engager platform. Our TriKE™ platform
Highlights
The debt has shrunk by 100% YoY
GTBP's EPS is down by 23% year-on-year but it is up by 8% since the previous quarter
GT Biopharma's equity has shrunk by 180% QoQ and by 122% YoY
The company's net income has shrunk by 73% YoY and by 7% QoQ
Key stats
What are the main financial stats of GTBP
Market
Valuations
Earnings
Shares outstanding
2.23M
Market cap
$5.27M
Enterprise value
$1.23M
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$14.36M
Net income
-$13.16M
EBIT
-$13.16M
EBITDA
-$13.16M
Free cash flow
-$12.9M
Per share
Balance sheet
Liquidity
EPS
-$6.94
EPS diluted
-$6.94
Free cash flow per share
-$6.8
Book value per share
-$0.75
Revenue per share
$0
TBVPS
$2.23
Total assets
$4.23M
Total liabilities
$5.9M
Debt
$0
Equity
-$1.67M
Working capital
-$1.67M
Debt to equity
0
Current ratio
0.72
Quick ratio
0.69
Net debt/EBITDA
0.31
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-174.5%
Return on equity
-468.1%
Return on invested capital
N/A
Return on capital employed
N/A
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
GTBP stock price
How has the GT Biopharma stock price performed over time
Intraday
-0.42%
1 week
-2.48%
1 month
-0.84%
1 year
-43.81%
YTD
-22.62%
QTD
9.77%
Financial performance
How have GT Biopharma's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$14.36M
Net income
-$13.16M
Gross margin
N/A
Net margin
N/A
The company's net income has shrunk by 73% YoY and by 7% QoQ
GTBP's operating income is down by 6% year-on-year and by 4.3% since the previous quarter
Growth
What is GT Biopharma's growth rate over time
Valuation
What is GT Biopharma stock price valuation
P/E
N/A
P/B
N/A
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
GTBP's EPS is down by 23% year-on-year but it is up by 8% since the previous quarter
GT Biopharma's equity has shrunk by 180% QoQ and by 122% YoY
Efficiency
How efficient is GT Biopharma business performance
GTBP's ROE has dropped by 93% since the previous quarter
The company's return on assets fell by 42% QoQ
Dividends
What is GTBP's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for GTBP.
Financial health
How did GT Biopharma financials performed over time
GT Biopharma's total assets is 28% less than its total liabilities
GT Biopharma's total assets has plunged by 70% YoY and by 37% from the previous quarter
GT Biopharma's quick ratio has shrunk by 67% YoY and by 51% QoQ
The debt is 100% higher than the equity
GT Biopharma's equity has shrunk by 180% QoQ and by 122% YoY
The company's debt to equity has shrunk by 100% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.